

**The American Brain Foundation**  
**Conflict of Interest Disclosure Statement**

Please complete this Statement and return it to the Chair of the Governance Committee.

I hereby acknowledge that I have: (1) received a copy of the Organization's Conflict of Interest and Disclosure Policy ("Policy"); (2) read and understood the Policy; and (3) agree to comply with the Policy.

The information set forth below is correct and complete to the best of my knowledge. During the time I am a director, officer, or Key Person of the Organization, I agree to keep this information up to date and promptly report any actual or possible Interest that is required to be disclosed under the Policy.

**I hereby disclose:**

- (1) All entities in which I hold a position as director, trustee, officer, owner (either as a sole proprietor or partner), member, or employee and with which the Organization has a relationship:

None

- (2) Any transaction in which the Organization is or may be a participant and as to which I may have a conflicting interest, either personally or through my Relative or business:

None

- (3) Any other situation which poses or may pose a conflict of interest.

My full disclosure statement is below. None conflict with my duties or responsibilities as an ABF board member and officer

Disclosure 2022: Consulting fees: Amgen, Novartis, Eli Lilly, Abbvie, Biohaven, Pfizer. Payment or honoraria for lectures, presentations: Amgen, Eli Lilly, Teva, Abbvie, Pfizer. Speakers Bureaus: None. Travel reimbursement: Abbvie (Canada). Participation on advisory board: Abbvie, Lundbeck, Biohaven, Pfizer, Nocira, Perfood, AYYA Biosciences. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: American Migraine Foundation, American Brain Foundation, International Headache Society Global Patient Advocacy Coalition. Precon Health, Ontologics, King-Devick technologies, Axon Therapeutics, Cephalgia Group. Stock or Stock Options; Aural analytics, Atria, Axon Therapeutics, Cephalgia Group, ExSano, Man and Science, Healint, Theranica, Second Opinion/Mobile Health, Epien, Nocira, Matterhorn, Ontologics, King-Devick Technologies, Precon Health, AYYA Biosciences, Atria Health. Financial or non-financial interests UNRELATED to this manuscript: Consulting: Amgen, Atria Health, CapThera Ltd., Cerecin, Cooltech, Ceruvia Lifesciences LLC, Ctrl M, Allergan, Biohaven, GSK, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Nocira, Perfood, Praxis, AYYA Biosciences, Revance. Honoraria: Vector psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, MJH Lifesciences, Miller Medical Communications, WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press. Research Support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI). Patent 17189376.1-1466.vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis (Non-royalty bearing). Patent application submitted: Synaquan (Precon Health)

Dated: Dec 26, 2022

Name: David W. Dodick

Signature: David W. Dodick, M.D.